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Background: Most PCR-based diagnostics are still considered time- and labor-intensive due to disparate purification,
amplification, and detection steps. Advancements in PCR enzymes and buffer chemistry have increased inhibitor
tolerance, facilitating PCR directly from crude samples. Obviating the need for DNA purification, while lacking a
concentration step, these direct sample methods are particularly apt for human genetic testing. However, direct
PCR protocols have traditionally employed thermal cyclers with slow ramp rates and conservative hold times that
significantly increase an assay ? s time-to-result. For this proof-of-principle study, our objective was to significantly
reduce sample preparation and assay time for a PCR-based genetic test, for myotonic dystrophy type 1 (DM1), by
pairing an inhibitor-resistant enzyme mix with a rapid thermal cycler to analyze samples directly in whole blood.
Methods: DM1 genetic screening was done with an adapted conventional PCR approach that employed the
Streck PhilisaW Thermal Cycler, the inhibitor-resistant NEBNextW High-Fidelity 2X PCR Master Mix, and agarose gel
electrophoresis or an Agilent 2100 Bioanalyzer for detection. The Gene Link? Myotonic Dystrophy Genemer ? Kit
was used as a reference assay kit to evaluate the rapid assay.
Results: In this work, a rapid and direct PCR assay testing 10% whole blood as template has been developed as
an exclusionary screening assay for DM1, a triple-repeat genetic disorder. PCR amplification was completed in 15
minutes using 30 cycles, including in situ hot-start/cell lysis. Out of the 40 donors screened, this assay identified
23 (57.5%) as DM1 negative suggesting no need for further testing. These data are 100% concordant with data
collected using the commercially available Gene Link Genemer ? Kit per the kit-specific PCR protocol.
Conclusions: The PCR assay described in this study amplified DM1 short tandem repeats in 15 minutes. By
eliminating sample purification and slower conventional PCR protocols, we demonstrated how adaptation of current
PCR technology and chemistries can produce a simple-to-use exclusionary screening assay that is independent of
up-front sample prep, improving a clinical lab technician? s time-to-result. We envision this direct and rapid methodology
could be applied to other conventional PCR-based genetic tests and sample matrices where genomic DNA is targeted
for analysis within a given molecular diagnostic platform.
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PCR-based testing, using whole blood as the DNA source,
is increasingly being used for forensic analysis, diagnosis
of microbial infection, detection of genetic disease, screen-
ing of organ transplants, blood banking, and prenatal
diagnosis [1-7]. Improvements to enzymes, specifically
hot-start formulations and recombinant engineering
modifications [8], have promoted adoption of PCR by
increasing assay robustness and convenience of reac-
tion preparation. However, a critical limitation of PCR
analysis is the time-consuming and costly DNA extrac-
tion steps often required for successful amplification of
DNA derived from clinical samples. Even with extraction,
PCR inhibitors can remain problematic and methods to
overcome false-negatives or reduced sensitivity must be
carefully selected to ensure the integrity of acquired data
[9-12]. Consequently, PCR enzymes and buffer chemistry
have been designed to amplify target sequences directly
from complex inhibitor-laden matrices such as whole
blood, soil, feces, and plants [13,14]. When working with
whole blood, common inhibitors of PCR include:
hemoglobin/heme, immunoglobulin G, lactoferrin, myo-
globin, and blood collection tube chemicals (i.e., EDTA,
heparin, and sodium citrate) [15].
The feasibility of such direct sample PCR techniques in
complex matrix backgrounds, in part, can be attributed to
the directed evolution of DNA polymerases. For example,
the engineering of chimeric enzymes, which combine
polymerase and protein-specific DNA binding domains,
have yielded polymerases with increased processivity
without compromising activity or stability [16]. Use of
site-directed mutagenesis has produced recombinant poly-
merases demonstrating a high resistance to inhibitors
[13,14,17]. Chemical additives and enzyme blends have
also provided a mechanism to overcome PCR inhibitors
and facilitate DNA amplification? even in the presence of
unpurified samples or templates with high GC content
[13]. Because each PCR inhibitor ? s mode of action can
vary, Barnes and coworkers demonstrated that a cocktail
of common additives (betaine, trehalose, L-carnitine, and
NP-40) improved PCR amplification from complex sam-
ple matrices [13]. Furthermore, the addition of these PCR
enhancer cocktails and an inhibition-resistant polymerase
to complex samples generally results in successful PCR
amplification.
In addition to inhibition-resistant buffers and polymer-
ases, one must consider the thermal cycling protocol
needed to implement a rapid direct-PCR assay. While the
reaction chemistries are fairly established, most PCR ramp
rates and hold times in direct sample assays have trad-
itionally been conservative to achieve the desired amplifi-
cation of target, especially by increasing the extension
time to allow the enzyme to persevere over inhibitors. Ap-
propriate pairing of direct sample PCR with fast thermalcycling and/or detection holds promise for unprecedented
time-to-results. Recently, Aboud and colleagues demon-
strated <25-minute forensic genotyping directly from FTA
buccal swabs using ultra-fast thermal cycling and a proto-
type Agilent bioanalyzer [18]. However, to our knowledge,
there have been no reports detailing the combination of
rapid cycling technology with a more technically challen-
ging and inhibitor-laden matrix such as whole blood. Add-
ing further challenge to direct sample methods, direct
PCR methods do not have a DNA concentration step;
therefore, a larger PCR sample volume is advantageous to
facilitate maximal template-to-volume input. The Streck
PhilisaW Thermal Cycler, due to the nature of the heat
transfer and sample tube design, maintains high ramp
rates and sample homogeneity with sample volumes up to
50 μl.
In this work, we describe a rapid and direct blood PCR
assay as a proof-of-principle to demonstrate amplification
of short tandem-repeat (STR) sequences designed to de-
tect myotonic dystrophy type 1 (DM1) alleles. DM1 is an
autosomal dominant disorder and is the most common
form of adult onset muscular dystrophy with an incidence
of about 1 in 8,000 individuals [19]. DM1 is characterized
by a CTG triple-repeat expansion in the 3′-untranslated
region of the DMPK gene [20]. Because severity of the dis-
ease correlates with the degree of repeat expansion, detec-
tion of ? normal? sized alleles has previously been used to
exclude samples with DM1-negative genotypes [21].
Guidelines for genetic testing of DM1 indicate the number
of CTG repeats range from 5 to 34 for a normal allele
[21]. Repetitions of 35 to 49 are considered pre-mutations;
carriers are generally asymptomatic, but genomic instabil-
ity of these repeats can put offspring at increased risk for
inheriting a larger allelic repeat size. When repeat lengths
are greater than 50, persons are often symptomatic and
severity usually correlates with increasing repeat length.
For diagnosis, conventional PCR can be used as the first
step in DM1 testing [19]. However, the test is most benefi-
cial when two normal size alleles are identified; in this
case, DM1 can be excluded and secondary methods of
analysis are not required [21]. On average, ~25% of
disease-negative population is homozygous with a normal
allele, which cannot be discriminated by conventional
PCR assays. Therefore, the presence of a single DM1 allele
does not confirm DM1 genotypes associated with disease
phenotype. These samples require follow-up testing with
triple-repeat PCR or Southern blotting methodology [21].
The purpose of this study was to demonstrate success-
ful PCR amplification of these genetic targets in 15 mi-
nutes for samples containing up to 30% whole blood.
Furthermore, a 30-cycle 15-minute DM1 PCR directly
from 10% crude whole blood was an optimal method to
demonstrate feasibility of a rapid direct PCR-based ap-
proach for detection of genomic DNA targets. Blood
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of DM1-associated allelic expansions. These data dem-
onstrate a synergistic coupling of a fast PCR cycling
strategy and direct blood PCR. The method is broadly
applicable and could be optimized with alternative gen-
etic targets and sample matrices. Although rapid and
direct PCR methods are still a work in progress, assays
such as this demonstrate promise for clinical use by de-
creasing sample handling and expediting analysis to re-
duce a molecular assay ? s time-to-result, providing a
more cost-effective solution for genetic analysis in the
clinic.
Methods
Blood donor recruitment and blood collection
This study was approved by the institutional review
board of the Methodist Hospital (Omaha, NE, USA) and
informed consent was obtained from all donors. All
blood donors were anonymous volunteers recruited
from Streck (Omaha, NE, USA). Both male and female
donors were tested and presumed to be healthy. A 10 ml
blood sample was drawn by venipuncture into a
K2EDTA blood collection tube (BD Vacutainer
W, Becton
Dickinson, Franklin Lakes, NJ U.S.A.) for each donor.
Blood was mixed well immediately after the draw by
inverting the tube 10 times.
Extracted DNA samples
Blood samples for direct addition to PCR sample mixes
were frozen and stored at −80 ?C until all aliquots were
acquired for analysis. Thawed blood was used for direct
PCR. For control samples, purified DNA from whole
blood was obtained using the AutoGen QuickGene-810
(Catalog No.: FI810; Holliston, MA, USA) with the
AutoGen DNA Whole Blood Kit (Catalog No.: FK-DBS).
PCR Amplification
The primer set for the myotonic dystrophy assay was
obtained from GeneLink (Catalog No.: 40-2026-10,
Hawthorne, NY USA) and yields a product size of 114 +
3 N bp, where N is the number of triple-repeats. NEBNextW
High-Fidelity 2X PCR Master Mix was provided by New
England BioLabs (Catalog No.: M0541, Ipswich, MA
USA). Each 25 μl reaction volume contained 0.5 μM of
each primer and 1X NEBNextW High-Fidelity PCR Master
Mix. Purified DNA or whole blood amounts for each reac-
tion were used as described in the text. For Figure 1,
3 mM MgCl2 was required for amplification of the DM1
alleles from 30% whole blood. The standard 1X mix has
2 mM MgCl2, and increasing this to 3 mM did not im-
prove amplification for other blood concentrations tested
in this study. All reactions used MB grade nuclease-free
water (Sigma, Catalog No.: W4502, St. Louis, MO USA).
A 2-step PCR protocol was carried out using the StreckPhilisaW Thermal Cycler (Catalog No.: 250000, Omaha,
NE USA) and Philisa PCR Tubes (Catalog No.: 250005):
Hot start of 98 ?C for 3 minutes, followed by 30 cycles of
[98 ?C for 6 seconds and 68 ?C for 12 seconds]. As a pro-
cedural control the Gene Link ? Myotonic Dystrophy
Genemer ? kit (Catalog No.: 40-2026-11, Hawthorne,
NY USA) was used as per manufacturer ? s instructions,
except PlatinumW Taq DNA Polymerase (Life Technolo-
gies, Catalog No.: 10966-026, Grand Island, NY USA) was
added to the PCR mix prior to the hot-start.
Analysis of PCR products
PCR products retained in the supernatant (after a 20-
second pulse on a picofuge to separate out cellular deb-
ris) were resolved by agarose gel electrophoresis and an
Agilent 2100 Bioanalyzer (Agilent Technologies, Loveland,
CO USA). For gel detection, 10 μl of PCR product was
stained with ethidium bromide and resolved on a 3% agar-
ose gel using TAE buffer. Imaging of ethidium bromide-
stained PCR product was done on a Molecular Imager
VersaDoc? (Bio-Rad; Hercules, CA USA). Bioanalyzer
sample analysis was carried out using the Agilent 1000
DNA kit (Catalog No.: 5067? 1504) as per manufacturer ? s
specifications.
Results and discussion
To demonstrate the utility and reliability of a rapid and
direct blood PCR approach, we used whole blood to
screen presumed healthy donors for the presence of nor-
mal DM1 alleles. As a comparative control, results were
compared to data collected using each donor ? s purified
DNA (pDNA) and a commercially available kit for DM1.
In the DMPK gene, 5 to 34 triple-repeats (normal alleles)
correspond to a DNA fragment size of approximately 129
to 216 bp (114 + 3 N), an amplicon size readily detected
with conventional PCR. Although PCR detection of ex-
panded (or even pre-mutation) alleles is ideal, our focus
with this assay was identification of DMPK alleles clearly
under the 216 bp cut-off. In this case, it is feasible that a
simple conventional PCR test can function as a negative
screen for exclusion of DM1 heterozygotes within the nor-
mal base pair range, i.e., when amplicon length clearly in-
dicates alleles of normal size [21]. If two normal alleles are
identified, DM1 can be excluded and secondary methods
of analysis are generally not required. However, since het-
erozygote frequency for the CTG repeats is ~75% in the
normal population, ~25% of unaffected individuals will be
homozygous for a given normal allele [21]. Therefore, the
presence of a single PCR band or a PCR band bordering
the molecular size threshold of normal and pre-mutation
is not meant to confirm a diagnosis of DM1. Alternatively,
these samples would require more quantitative testing,
such as Southern blot or triple-repeat PCR [21], to deter-
mine the presence of expanded alleles. In compliance with
Figure 1 Investigation of % blood tolerance of the rapid PCR
assay. Increasing concentrations of whole blood (5, 10, 20, or 30%), as
indicated, were added to the PCR tube. Products resolved by agarose
gel electrophoresis. M (100 bp marker); P (10 ng of purified donor
DNA); D14 (Donor 14); D15 (Donor 15); N (no template control).
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mal, pre-mutation, or expanded alleles, exact repeat sizing
for the assay described here is not a necessity if both het-
erozygous alleles fall within the normal molecular size
range and are detected with a standard PCR assay [21].
However, the exact allele size is imperative when conven-
tional methods produce unclear data that does not dis-
criminate an expanded pre-mutation or fully penetrant
allele. Pre-mutation alleles are not associated with a clin-
ical phenotype in the carrier but can expand in future gen-
erations; however, fully penetrant alleles are associated
with a disease phenotype [21].
To determine if a rapid PCR assay could detect DM1
normal alleles directly from blood, we tested assay toler-
ance with increasing blood concentrations for two differ-
ent donor samples using multiple polymerases and master
mixes (data not shown). During enzyme and buffer
screening, most enzymes advertised for direct PCR ana-
lysis were not compatible with the shortened hold times
favored in rapid PCR protocols. Conversely, many high-
fidelity polymerases that successfully amplified target from
pure DNA samples, using the Philisa 15-minute cycling
protocol, did not amplify target when whole blood was
added directly to the master mix. For the purposes of our
study, the NEBNext High-Fidelity 2X PCR Master Mix
was used because it produced PCR product successfully
for both rapid cycling and direct-blood analysis when
paired with the Philisa Thermal Cycler. Data from Figure 1
indicate the assay could tolerate up to 30% whole blood in
a given PCR reaction tube and the cycling time was com-
pleted in 15 minutes, including a 3-minute hot-start/cell
lysis step. Some qualitative loss of band intensity is ob-
served during testing of whole blood concentrations at
30%, which likely results from increased inhibitor concen-
tration scaled alongside increased template input. Increas-
ing MgCl2 concentration in the reaction buffer by 1 mM
improved amplicon resolution on the gel for samples
tested at 30% whole blood. Donors 14 and 15 in Figure 1
provide an example of heterozygous and homozygous
DM1 alleles, respectively. Based on Figure 1 data for
donor 14, PCR using DM1-specific primers detected
two amplicons that clearly resolve below the 216 bp
cut-offs for normal allele sizing and, as such, is an ex-
ample of a DM1 negative genotype. However, donor 15
would require further testing to determine if the patient
carries a higher molecular weight repeat expansion or is
homozygous for the normal allele. Data from Figure 1
demonstrates the application of this test as a rapid ex-
clusionary screening assay for DM1.
Using the same 15-minute PCR assay with optimized
whole blood concentration set at 10%, we increased our
sample set to 40 donors to test the reliability of detec-
tion methods by using both agarose gels (Figure 2) and
an Agilent bioanalyzer (Figure 3). Gel data, concordantbetween purified DNA and whole blood, identified 23 of
the 40 donors as negative for DM1; this is indicated by the
presence of two molecular weight bands between ~129 to
216 bp and clearly under the 216 bp normal allele cut-off.
As such, 17 of the 40 donors would require further testing
to determine their disease status. Of the donors tested,
57.5% of our sample set were heterozygous for the DM1
allele and would have been identified as negative for DM1:
a value 20% lower than the global population average.
To this end, we investigated whether the improved de-
tection sensitivity of an Agilent bioanalyzer could reveal
any additional heterozygous donor alleles that were not
readily resolved on an agarose gel. The bioanalyzer data
(both purified DNA and whole blood results) did strongly
support gel data for the 23 donors detected as heterozy-
gotes and DM1-negative as well as the 17 donors that
needed further testing (Figure 2). However, for three do-
nors (8, 11, and 36; Table 1, Figures 3 and 4) characterized
as homozygotes by gel electrophoresis data, the bioanaly-
zer produced split peaks. Based on our manual interpret-
ation of the data and the resolution sensitivity of the
assays, it is possible that the DM1 alleles for these donors
are a CTG repeat apart (Figure 4C); however, this is a size
difference outside the resolution limits of both an agarose
gel and the bioanalyzer. For example, the DNA 1000 kit
user manual indicates a 200 bp fragment detected with
the Agilent bioanalzyer has a 5% error when resolving 100
to 500 bp amplicons, a resolution too low to resolve a
single CTG repeat. Alternatively, we cannot rule out that
the split peaks are a product of incomplete amplicon ex-
tension during the PCR. In these cases, the results are
questionable and should be interpreted as in need of fur-
ther testing. In agreement with agarose gel data, the het-
erozygous donors detected with the Agilent bioanalyzer
are still below the global heterozygous frequency. These
differences could be attributed to (1) the very small and
localized population sample set, (2) decreased size reso-
lution compared to other detection methods, and (3) the
inability to identify pre-mutation and expanded alleles.
Furthermore, in contrast to gel electrophoresis data, the
bioanalyzer results required careful interpretation. In
some of the samples, spurious peaks and baseline artifacts
(Figure 4C and E) arose, likely due to the increased detec-
tion sensitivity of the bioanalyzer. For example, in some
Figure 2 Rapid PCR screening of DM1 with agarose gel detection. 10 ng purified donor DNA (P) or 10% direct whole blood (B) from 40
numerically-indicated donors with detection using agarose gel electrophoresis. N (no template control); M (marker; the 200 to 100 base pair range
is indicated).
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a broad peak around 220 bp (Figure 4C) were observed.
Gel lanes for no template control (NTC) samples did not
resolve any amplicons, which suggests contamination of
the PCR master mix was not an issue (Figure 3; see gel
lanes marked N). Given that the intensities of these peaks
were small relative to clear product peaks, we dismissed
them as artifacts. Denoting these as artifacts is considered
a valid assumption for samples in which two higher inten-
sity heterozygote peaks are also clearly present. For sam-
ples where one clear product peak is present along with
questionable peaks, we called these samples as homozy-
gotes (Figure 4D). Regardless of homozygote or question-
able call notation, more quantitative tests are necessary to
discriminate between artifact, pre-mutation, or a fully
penetrant allele. In another aspect, for some whole blood
samples the product peaks fell below the default software
threshold of 20 fluorescent units (Figure 4B). However, weFigure 3 Rapid PCR screening of DM1 with Agilent bioanalyzer detec
40 numerically-indicated donors with detection using the Agilent 2100 Bio
100 base pair range is indicated).interpreted these as product peaks by manual calling given
the accompanying clean baseline and supporting agarose
gel data. Lastly, for some donors, signal was greater for
DM1 amplicons in the whole blood amplification vs. puri-
fied DNA and vice versa. Even with consistent sample
mixing, it cannot be assumed that whole blood samples
added to each PCR tube in the direct blood assay had
equivalent DNA concentration compared to the 10 ng
purified DNA controls. Furthermore, PCR product-
trapping in red cell debris pellets may result in minor
sample loss during the post-PCR centrifugation step.
Table 1 provides a summary of all donors that indicates
results with the rationale for their assignment following
assay screening.
To further substantiate the rapid and direct PCR re-
sults described herein, all purified donor DNA was
tested using the Gene Link Genemer Kit (Figure 5). The
PCR cycling protocol for this kit takes greater thantion. 10 ng purified donor DNA (P) or 10% direct whole blood (B) from
analyzer DNA 1000 kit. N (no template control); M (marker; the 200 to
Table 1 Bioanalyzer data summary for DM1 direct blood PCR results
Donor(s) Result Resolution
1, 2, 3, 5, 6, 7, 9 14, 17, 22,
23, 24, 30, 34, 38, 39
Heterozygote Both gel and bioanalyzer data indicate bands or peaks, respectively, consistent with
two alleles within the specified base pair range for a normal DM1 phenotype.
Detected peaks were above the bioanalyzer? s assay 20 FU default threshold for both
purified DNA and 10% whole blood. No further testing needed.
18, 20, 26, 29, 31, 32, 35 Heterozygote-Manual Call* The purified DNA sample and 10% whole blood sample both indicate heterozygote.
However, for 10% whole blood samples, agarose gel detection indicated low band
intensity and bioanalyzer electropherogram peaks were under the 20 FU default
threshold.
8, 11, 36 Gel: Homozygote Bioanalyzer:
Heterozygote ? Split-Peak? *
The PCR product(s) for this donor sample have an apparent split peak when detected
by the Agilent bioanalyzer. Agarose gel data indicate a single band. If reported
bioanalzyer resolution is accurate, the split peak would indicate a tandem repeat
difference of 5? 10 base pairs for these DM1 amplicons.
12, 13, 15, 19, 25, 27, 33,
37
Homozygote* Both gel and bioanalyzer data indicate bands or peaks, respectively, consistent with
one allele within the specified base pair range for a normal DM1 phenotype. Further
testing is recommended to determine if there is a DM1 repeat expansion.
4, 10, 16, 21, 28, 40 Homozygote-Artifacts* Agarose gel data for this sample indicate a single clear band for both purified DNA
and 10% whole blood. However, for the more sensitive bioanalyzer studies, smaller
peaks corresponding to larger base pair fragments were identified. We speculate
these peaks are non-specific PCR amplification products. Peaks detected with the
bioanalyzer, falling under the assay? s 20 FU default threshold, were interpreted as
artifacts. Further testing would be required to determine DM1 status for this patient.
*Donors with the following results would require further testing based on bioanalzyer data.
Figure 4 Selected bioanalyzer electropherogram overlays from purified DNA (red) or 10% whole blood (blue). Results from five representative
donors illustrate examples of a confirmed heterozyote (A), heterozygote with a 10% blood under the default FU cutoff (B), and suspected heterozygote
with split peaks as an allelic differentiator and a larger artifact (C), confirmed homozygote (D), homozygote with two smaller artifacts (E).
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Figure 5 DM1 screening using the Gene Link Genemer Kit with Agilent bioanalyzer detection. 100 ng purified donor DNA (P) from 40
numerically-indicated donors with detection using the Agilent 2100 Bioanalyzer DNA 1000 kit. N (no template control); M (marker; the 200 to 100
base pair range is indicated).
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DNA per reaction. In support of the results produced
using the rapid and direct assay, the data for these ex-
periments suggests the same 23 of 40 donors were het-
erozygous and had two normal sized DM1 alleles.
Electropherograms for this data are also consistent with
data collected in Figure 4; additional peaks were noted
and similar to those detected with the rapid and direct
PCR protocol (Figure 6). Because the samples tested inFigure 6 Selected bioanalyzer electropherogram overlays from purifie
Kit. Results from five representative donors illustrate examples of a confirmed
cutoff (B), and suspected heterozygote with split peaks as an allelic differentia
with two smaller artifacts (E).these experiments were not previously characterized
with more quantitative methods, we cannot use the data
to draw a clinical conclusion. However, data for Figures 5
and 6 indicate our 15-minute rapid PCR assay produces
similar results to a commercially available kit; it supports
the proof-of-concept that this assay could be validated
for conventional PCR testing of DM1 genetic targets
from whole blood samples as an exclusionary screening
assay.d DNA (red) using the Gene Link Myotonic Dystrophy Genemer
heterozyote (A), heterozygote with a 10% blood under the default FU
tor and a larger artifact (C), confirmed homozygote (D), homozygote
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post-PCR analysis platform that reduces the ~60-minute
run time of an agarose gel to 35 minutes; this makes the
total assay time-to-result for this direct blood method
50 minutes. Even though the bioanalyzer does appear to
give better heterozygote resolution and approximate
(but unnecessary) sizing, the trade-offs are increased
cost and peak interpretation to include/exclude actual
vs. artifact peaks. As such, we would only recommend
using agarose gel data that clearly indicate two ampli-
cons within the prescribed base pair range and proceed
with additional testing for all other samples. While time-
to-result for myotonic dystrophy screening is not of
grave importance, the sheer convenience of the rapid
technique is advantageous for lab productivity and fits
typical screening of individuals and families. Although
the immediate goal of this work was to focus strictly on
the rapid direct PCR assay feasibility, future work with
the DM1 assay could test known clinical samples in a
head-to-head comparison of this method to a ? gold
standard ? assay for call verification; future work would
involve pre-mutation and expanded allele validation as
well as implementation on genetic analyzer platforms
using fluorescently labeled primers. It is expected that
larger pre-mutation-sized alleles can be detected with
the assay; i.e., an increase to the repeat sizes is likely to
be captured, especially with minimally increased cycling
extension times.Conclusions
In conclusion, the experiments described in this study
demonstrate successful amplification of the triple-repeat
disorder DM1 directly from whole blood using a rapid
15-minute PCR protocol that includes a hot-start/cell
lysis step. The pairing of rapid thermal cycling and direct
sample PCR creates a fast and convenient assay. It cir-
cumvents laborious DNA purification methods and can
be adapted to other, more specific molecular applica-
tions and sample matrices, especially where genomic
DNA contains the target(s) of interest. For example, de-
pending on the load present in blood, pathogen detec-
tion may also be amenable to direct PCR. Since PCR
sensitivity can be an issue critical to pathogen detection,
a sample enrichment process or higher concentrations
of whole blood may be required for this type of analysis.
The assay developed herein has significant potential to
provide benefit to molecular labs by improving sample
turnaround times, expediting time-critical results, and
increasing lab productivity.
Abbreviations
DM1: Myotonic dystrophy type 1; STR: Short tandem repeat; PCR: Polymerase
chain reaction; DNA: Deoxyribonucleic acid; pDNA: Purified DNA; NTC: No
template control; RBC: Red blood cell; WBC: White blood cell; bp: Base pairs.Competing interests
The authors are employed by Streck, the manufacturer of the Philisa Thermal
Cycler.
Authors ? contributions
CMC contributed to the conception, experiments, figures, development of
the assay, wrote and edited the manuscript. JRT contributed to the conception,
experiments, figures, development of the assay, wrote and edited the
manuscript. LRP contributed to the design and completion of experiments
and figures and editing of the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
This research was funded by Streck, Inc. We would like to thank Dr. Tom
Williams, Joel Lechner and M. Rohan Fernando for their critical evaluation of
this manuscript.
Received: 17 October 2013 Accepted: 24 November 2014
References
1. Bussani C, Cioni R, Mattei A, Fambrini M, Marchionni M, Scarselli G: Prenatal
diagnosis of common aneuploidies in transcervical samples using
quantitative fluorescent-PCR analysis. Mol Diagn Ther 2007, 11(2):117? 121.
2. Cursons RT, Jeyerajah E, Sleigh JW: The use of polymerase chain reaction to
detect septicemia in critically ill patients. Crit Care Med 1999, 27(5):937? 940.
3. Deng Z, Wu G, Li Q, Zhang X, Liang Y, Li D, Gao S, Lan Y: Noninvasive
genotyping of 9 Y-chromosome specific STR loci using circulatory fetal DNA
in maternal plasma by multiplex PCR. Prenat Diagn 2006, 26(4):362 ? 368.
4. Espy MJ, Uhl JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA, Yao JD,
Wengenack NL, Rosenblatt JE, Cockerill FR 3rd, Smith TF: Real-time PCR in
clinical microbiology: applications for routine laboratory testing.
Clin Microbiol Rev 2006, 19(1):165 ? 256.
5. Lo YM, Leung TN, Tein MS, Sargent IL, Zhang J, Lau TK, Haines CJ, Redman CW:
Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia.
Clin Chem 1999, 45(2):184? 188.
6. Rautenberg P, Lubbert C, Weers W, Boetel E, Schweichler J, Zhou L, Costard-
Jackle A, Kraemer-Hansen H, Harder TC: Evaluation of the AmpliSensor
PCR and the SHARP signal detection system for the early prediction of
symptomatic CMV infection in solid transplant recipients. J Clin Virol
1999, 13(1 ? 2):81? 94.
7. Robertson JM, Walsh-Weller J: An introduction to PCR primer design and
optimization of amplification reactions. Methods Mol Biol 1998, 98:121 ? 154.
8. Kranaster R, Marx A: Engineered DNA polymerases in biotechnology.
Chembiochem 2010, 11(15):2077 ? 2084.
9. Dauphin LA, Hutchins RJ, Bost LA, Bowen MD: Evaluation of automated
and manual commercial DNA extraction methods for recovery of
Brucella DNA from suspensions and spiked swabs. J Clin Microbiol 2009,
47(12):3920? 3926.
10. Dauphin LA, Moser BD, Bowen MD: Evaluation of five commercial nucleic
acid extraction kits for their ability to inactivate Bacillus anthracis spores
and comparison of DNA yields from spores and spiked environmental
samples. J Microbiol Methods 2009, 76(1):30 ? 37.
11. Kramvis A, Bukofzer S, Kew MC: Comparison of hepatitis B virus DNA
extractions from serum by the QIAamp blood kit, GeneReleaser, and the
phenol-chloroform method. J Clin Microbiol 1996, 34(11):2731? 2733.
12. Schuurman T, van Breda A, de Boer R, Kooistra-Smid M, Beld M, Savelkoul P,
Boom R: Reduced PCR sensitivity due to impaired DNA recovery with the
MagNA Pure LC total nucleic acid isolation kit. J Clin Microbiol 2005,
43(9):4616? 4622.
13. Zhang Z, Kermekchiev MB, Barnes WM: Direct DNA amplification from
crude clinical samples using a PCR enhancer cocktail and novel mutants
of Taq. J Mol Diagn 2010, 12(2):152? 161.
14. Kermekchiev MB, Kirilova LI, Vail EE, Barnes WM: Mutants of Taq DNA
polymerase resistant to PCR inhibitors allow DNA amplification from
whole blood and crude soil samples. Nucleic Acids Res 2009, 37(5):e40.
15. Schrader C, Schielke A, Ellerbroek L, Johne R: PCR inhibitors - occurrence,
properties and removal. J Appl Microbiol 2012, 113(5):1014? 1026.
16. Wang Y, Prosen DE, Mei L, Sullivan JCM, Vander Horn PB: A novel strategy
to engineer DNA polymerases for enhanced processivity and improved
performance in vitro. Nucleic Acids Res 2004, 32(3):1197 ? 1207.
Connelly et al. BMC Medical Genetics 2014, 15:130 Page 9 of 9
http://www.biomedcentral.com/1471-2350/15/13017. Loh E, Choe J, Loeb LA: Highly tolerated amino acid substitutions
increase the fidelity of Escherichia coli DNA polymerase I. J Biol Chem
2007, 282(16):12201 ? 12209.
18. Aboud M, Oh HH, McCord B: Rapid direct PCR for forensic genotyping in
under 25 min. Electrophoresis 2013, 34(11):1539 ? 1547.
19. Kamsteeg EJ, Kress W, Catalli C, Hertz JM, Witsch-Baumgartner M, Buckley
MF, van Engelen BG, Schwartz M, Scheffer H: Best practice guidelines and
recommendations on the molecular diagnosis of myotonic dystrophy
types 1 and 2. Eur J Hum Genet 2012, 20(12):1203 ? 1208.
20. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H,
Hunter K, Stanton VP, Thirion JP, Hudson T: Molecular basis of myotonic
dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a
transcript encoding a protein kinase family member. Cell 1992, 69(2):385.
21. Prior TW, American College of Medical Genetics Laboratory Quality
Assurance C: Technical standards and guidelines for myotonic dystrophy
type 1 testing. Genet Med 2009, 11(7):552? 555.
doi:10.1186/s12881-014-0130-5
Cite this article as: Connelly et al.: PCR amplification of a triple-repeat
genetic target directly from whole blood in 15 minutes as a proof-of-
principle PCR study for direct sample analysis for a clinically relevant
target. BMC Medical Genetics 2014 15:130.Submit your next manuscript to BioMed Central
and take full advantage of: 
? Convenient online submission
? Thorough peer review
? No space constraints or color ?gure charges
? Immediate publication on acceptance
? Inclusion in PubMed, CAS, Scopus and Google Scholar
? Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
